Adenovirus (HAdV) infections are a frequent cause of morbidity and mortality after allogeneic human stem cell transplantation (HSCT). We report a retrospective singlecentre study on 328 consecutive paediatric recipients of an allogeneic HSCT. During the first 6 months after HSCT, HAdV infection occurred in 37 children (cumulative incidence 12%). The highest incidence was found in young children up to 5 years of age, transplanted after 1994, with 42 log T-cell depletion of a graft of another than an HLA-genotypically identical related donor (actuarial frequency at 6 months 84%). Persistence of HAdV and spreading of the virus over multiple sites showed a trend towards the development of HAdV disease or death, but did not reach significance. Recovery of immunity after HSCT, that is, serum concentrations of IgM and peripheral blood counts of T cells and subsets, was delayed in children with an HAdV infection compared with noninfected children. In seven out of seven patients with HAdV DNA in serum and decreasing lymphocyte counts, the infection had a fatal course. Manipulation of cellular immunity either by tapering of immunosuppression, infusion of donor lymphocytes or immunotherapy using HAdV-specific T cells should be considered in graft recipients at risk for a severe HAdV infection.
mune recovery
Infectious complications are a major cause of morbidity and mortality after allogeneic haematopoietic stem cell transplantation (HSCT). Especially since the early 1980s, reactivations of latently present DNA viruses were frequently observed. This is related to the introduction of other donors than HLA-genotypically identical related donors (IRD, identical related donor, either siblings or other family members) and T-cell depletion (TCD) of the graft, in order to prevent acute graft-versus-host disease (GvHD), Besides potentially lethal infections with cytomegalovirus (CMV) 1, 2 and Epstein-Barr virus (EBV), 3, 4 infections with adenoviruses (HAdV) were reported to occur with increasing frequency in the 1990s. HAdV infections were especially noticed in paediatric graft recipients, starting between 2 and 8 weeks after HSCT [5] [6] [7] [8] [9] [10] [11] [12] and being lethal in up to 50% of cases [9] [10] [11] (for a review, see Walls et al 13 and Kojaoghlanian et al 14 )
. Except for one study, 5 the incidence of HAdV infection was found to be higher after HSCT with a matched unrelated donor (MUD) or an other than HLA-genotypically identical related donor (ORD, other related donor), mostly a haploidentical parent, than after HSCT with an IRD. 7, 8, 10, 11 In previous reports, the occurrence of acute GvHD grade X2 and isolation of HAdV from multiple sites were identified as risk factors for morbidity following HAdV infection. [9] [10] [11] 15, 16 However, from these studies it remained unclear whether the degree of immune recovery after HSCT was related with the occurrence or the course of an HAdV infection. Recently, it has been reported that severe lymphocytopenia at the first detection of HAdV after HSCT was associated with the development of HAdV disease. 17 In addition, recent studies indicate that the persistent presence of HAdV DNA in serum or plasma and an increasing load was associated with a fatal outcome of the infection. [18] [19] [20] However, data on immune recovery were lacking in these studies.
Here, we report the results of a retrospective single-centre cohort study, including all consecutive paediatric recipients of an allogeneic HSCT transplanted in a period of 14 years, from 1985 onwards. The incidence and clinical course of HAdV infections were analysed in relation with several transplant-related variables and virological and immunological parameters. Results were used to define specific risk factors for occurrence of HAdV infection and the development of HAdV morbidity and mortality. Based on the findings of this retrospective study, strategies for the prediction of HAdV dissemination and the pre-emptive treatment of HAdV infection are proposed.
Methods

Patients and SCT procedures
Between January 1985 and January 1999, 328 infants and children received an allogeneic HSCT for different malignant and nonmalignant diseases in the paediatric bone marrow transplant centre of the Leiden University Medical Centre. Majority of the patients (n ¼ 315) were treated with bone marrow cells; a small number received either T-celldepleted peripheral blood stem cells (n ¼ 7) or unmanipulated cord blood cells (n ¼ 6). Bone marrow grafts from IRD were always full grafts without any manipulation; grafts from ORD or MUD were frequently T-cell depleted, using either E-rosetting and albumin gradient centrifugation, 21 immunorosetting, 22 Campath-1G 'in the bag' 23 or CD34 þ stem cell enrichment by CliniMACS. 22 Conventional E-rosetting gave a TCD of p2 log, immunorosetting using anti-T cell (and sometimes also anti-B cell) monoclonal antibodies and Campath-1G 'in the bag' resulted in a 2-3 log TCD, and CD34
þ selection gave a TCD of 43 log. Patient characteristics, donor types and graft manipulations are summarized in Table 1 .
The pretreatment of the graft recipient was according to the disease-specific protocols of the relevant working parties of the European Group for Blood and Marrow Transplantation (EBMT). In order to prevent rejection and to promote engraftment in MUD/ORD HSCT settings, monoclonal antibodies (eg Campath-1G and -1H, aLFA-1, aCD2, and ATG) alone or in various combinations were given as immunosuppression shortly before or over the transplant date. All patients were cared for in a strict protective isolation during a total period of at least 5 weeks, using aseptic nursing techniques, antimicrobial suppression of the potentially pathogenic gastrointestinal microflora and sterilized food and beverages, as described before. 24 Except for pneumocystis pneumonia, prophylaxis with cotrimoxazol from 3 weeks post-HSCT onwards, neither systemic antibacterial nor antiviral prophylaxis was given; only pre-emptive treatment for CMV and treatment for symptomatic infections was applied. Graft-versus-hostdisease (GvHD) prophylaxis consisted of either MTX or CSA alone (n ¼ 89) or the combination of CSA during X6 months plus a short course of MTX (n ¼ 222). GvHD treatment consisted of 2 mg/kg body weight of methylprednisolone i.v. per day, for 1-2 weeks, followed by tapering of the dose; additional treatment, such as mycophenolate mofetil or thalidomide, was rarely given. The severity of acute GvHD was graded according to Glucksberg et al 25 and that of chronic GvHD according to Shulman et al. 26 Failure of engraftment or early rejection was observed in 30 cases, from which 20 received a second transplant. In these cases, only the period of 6 months after the first HSCT was included in the evaluation. This study was approved by the Institutional Review Board on Medical Ethics.
Adenovirus infection and disease
The following microbiological and clinical definitions were used in this study. HAdV infection was defined as the laboratory identification of the virus by culture in a sample of faeces, throat swab or urine. HAdV disease was considered to be present when clinical signs and symptoms such as fever, haemorrhagic cystitis or enteritis, upper or lower respiratory tract infection, possibly confirmed by Xray (ie localized disease) or manifestations of infection in other organs such as the liver and the central nervous system (ie disseminated disease) were present in patients with an HAdV infection and without an alternative explanation for the disease. The identification of HAdV in tissue specimens taken at biopsy or at autopsy was the definitive proof of HAdV disease and HAdV-related death, respectively.
The virological surveillance consisted of routine cultures of faecal and urine samples and throat swabs performed at a frequency of once in 1-2 weeks during the period of hospital stay, and on clinical indication for outpatients up Quantification of the adenovirus DNA load in serum samples was performed with HAdV-specific primers and probes were selected from the 3 0 end of the hexon gene as described by Claas et al. 27 Serum samples of each patient were collected weekly during hospital stay and at regular visits to the outpatient clinic, stored at -201C and retrospectively investigated. DNA was isolated using spin columns of the QiaAmp Blood kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. In total, 10 ml of this DNA was subjected to real-time PCR amplification using the iCycler IQt Multi-Color Real Time PCR Detection system (BioRad, Veenendaal, The Netherlands). The PCR was performed as a multiplex assay in a 50 ml volume containing 2 Â HotStar Taq Master mix (Qiagen GmbH, Hilden, Germany) and contained three HAdV-specific primers: HAdVs (CATGACTTTTGAGGT GGATC), HAdV31s (TATGACATTTGAAGTTGACC), HAdVas (CCGGCCGAGAAGGGTGTGCGCAGGTA) and two molecular beacons, the 6-carboxy-fluorescein (FAM)-labeled ADV-MB-AC (GCTGCG GAGCCYAC CCTTCTTTATGT CGCAGC) for species A and C virus detection and the hexachloro-fluorescein (HEX)-labeled ADV-MB-B (CGTGCG GAGCCCACCCTGCTTTATCT CGCACG) for species B virus detection. The stem sequences of the molecular beacons are underlined. The amplification protocol consisted of an enzyme activation step of 951C for 15 min, followed by 50 cycles of amplification (951C for 30 s, 551C for 30 s and 721C for 30 s). A fixed amount of Phocine Herpes Virus (PhHV) was added as an internal control prior to extraction and was coamplified in the multiplex reaction to check for DNA isolation and inhibition as described previously. 28 A TexasRed labeled ADV-MB-F probe (CGTGCG GAGCCCA CACTTCTYTATGT CGCACG) was designed to quantify the viral DNA of an HAdV 41-positive patient, but this probe was not added to the multiplex reaction.
The oligonucleotide primers were synthesized by Eurogentec (Seraing, Belgium) and the molecular beacons by Biolegio (Malden, The Netherlands).
Immunological recovery
T-cellular recovery was assessed by the evaluation of blood counts of CD3 þ T cells, CD3 þ CD4 þ and CD3 þ CD8 þ Tcell subsets (FACS analysis) at three time intervals during follow-up with each time interval covering 2 months. During the period of the study, FACS analysis was performed for every patient at regular time points after HSCT and results were collected in a database. If these data were not available due to low numbers of lymphocytes (o100/ml), the absolute blood count of CD3 þ T cells was arbitrarily set at the number of lymphocytes in peripheral blood, and the counts of each of the T-cell subsets at 50% of this number. First, normal immunological recovery at the different time intervals was defined by investigating patients with engraftment and without early rejection who did not show HAdV infection. All cell counts were log transformed to obtain a normal distribution. When cell counts were available at several time points during a time interval, the median value was taken. As a parameter of the recovery of humoral immunity, the serum levels of IgM, IgG and IgA were analysed likewise. Concentrations were quantified using radial immunodiffusion techniques with polyclonal isotype-specific antisera from Nordic (Tilburg, The Netherlands) or by nephelometry (BN 100 nephelometer and antisera, Dade Behring, Marburg, Germany). The levels of Ig-isotypes were compared with normal values of age-matched healthy children. 29 More detailed studies, for example, in vitro proliferation tests or specific antibody determinations were not routinely performed in the first 3 months post-HSCT.
Statistical procedures and evaluation of data
Cumulative incidence of HAdV infection was estimated using Kaplan-Meier product limit methods. The occurrence of HAdV infection, as evidenced by at least one positive culture during the first 6 months after HSCT, was taken as primary outcome. Event-free patients were censored at the end of the study period of 6 months. Patients who died during follow-up due to causes not related to HAdV infection were censored at the time of death. Risk factors for the occurrence of HAdV infection were determined by the log rank test and by univariate and multivariate Cox proportional hazards analysis. The following baseline parameters were considered: (1) donor type, (2) manipulation of the graft, (3) HSCT period, (4) age of the recipient at HSCT, (5) gender of the recipient, (6) original disease, (7) GvHD prophylaxis and, only in the group of patients after MUD/ORD HSCT, (8) immunosuppression 'in the conditioning'. Since failure of engraftment/early rejection and acute GvHD become apparent early after transplantation, these parameters were also modelled as fixed variables.
Chronic GvHD, second HSCT and multiplicity and persistence of infection, respectively, were analysed by chisquare test. Incidence of HAdV-related death among HAdV-infected patients was assessed using Kaplan-Meier product limit methods. To evaluate risk factors associated with HAdV disease and HAdV-related death among HAdV-infected cases, logistic regression analysis was carried out, including the same baseline parameters as mentioned above.
Immunological recovery was investigated only in the group of patients after MUD/ORD HSCT. Differences between HAdV-infected patients, cases with HAdV disease and cases with HAdV-associated death, respectively, and noninfected recipients were evaluated by T-tests for comparison of means at the three different time intervals.
Results
Incidence of adenovirus infection
HAdV infection, as demonstrated by one or more positive culture results, occurred in 44 of the 328 patients. However, in seven of them HAdV-positive cultures were only found outside the study period of 6 months after the first HSCT, that is, either only before (n ¼ 2) or later than 6 months after the first HSCT (n ¼ 5). One child of the latter group died 3 months after a second HSCT from encephalitis associated with HAdV as confirmed at autopsy. In conclusion, 37 children presented with HAdV infection during the study period of 6 months after the first HSCT. Six of the 37 patients (original disease: SCID n ¼ 2; ALL n ¼ 2; thalassaemia and Blackfan Diamond anaemia, respectively) already had positive culture results prior to HSCT, which persisted after HSCT. All six patients were younger than 4 years at transplantation, and three of them were even less than 1 year of age. Table 2 shows the distribution of HAdV infections and the outcome of the infection, that is, HAdV disease and HAdV-associated death, within the whole study cohort in relation to characteristics of the patient, and to HSCT-related baseline parameters.
The Kaplan-Meier estimated cumulative incidence of HAdV infection during the first 6 months after HSCT was 12.0%. The incidence of HAdV infections increased considerably in more recent years, ranging from 5.4% in the period 1985-1994 to 22.5% in the period 1995-1998. Table 3 shows the outcome of the HAdV infection in relation to various virological parameters, such as the positive culture sites, the multiplicity of positive cultures, that is, one single day or on various occasions, and the isolated HAdV serotype. HAdV disease occurred in 17 of the 37 (45.9%) infected cases, expressing itself as enteritis (n ¼ 15), haemorrhagic cystitis (n ¼ 3, combined with enteritis in 2), pneumonia (n ¼ 1) and hepatitis (n ¼ 3, all combined with enteritis). Seven of the 17 patients with HAdV disease died (ie overall incidence 2.1% in the study population), three with fulminant hepatitis with severe clotting disturbance, two with protracted haemorrhagic cystitis, one with (haemorrhagic) enteritis and one with pneumonia. HAdV-related hepatitis, associated with a steep rise of aminotransferases (SGPT, SGOT and gamma-GT) to serum levels more than five times above the upper limit of the normal range followed by a continuous increase, became apparent at 2, 8 and 14 days, respectively, before decease. Spreading of HAdV over multiple sites showed a trend (P ¼ 0.07) to correlate with disease severity, without reaching significance: seven out of 10 patients with positive cultures of HAdV from multiple sites had HAdV disease or died from HAdV infection as compared to 10 out of 27 patients with HAdV isolation from a single site. In Table 4 the day of first HAdV isolation is given in relation with the transplantation date and the duration of the presence of positive samples. For the whole group of HAdV-infected children, infection started from 85 days before HSCT until 157 days after HSCT (median þ 44 days). Clinical symptoms started between 160 days prior to HSCT (ie in a patient treated for SCID) and 164 days post-HSCT (median þ 68 days). Persistence of the virus for more than 14 days was observed in all seven patients with a lethal infection. However, persistence as such is not a strong indicator of fatal outcome of the infection, since persistence was also observed in 40% (eight out of 20) of children without HAdV disease or death (positive predictive value 60%).
Clinical and virological findings
Owing to the limited panel of antisera available, HAdV isolates could not be typed in 11 of the 37 cases. Of the 26 typable HAdV strains, 17 belonged to species C (HAdV 1, 2, 5 and 6, see Table 3 ). No clear relation between the infectious HAdV strain or species and the clinical outcome was observed. In only one out of the six children with positive culture results before transplant, the infectious HAdV strain identified prior to HSCT (type 2) differed from the infectious strain isolated after HSCT (type 5).
Patient-and transplant-related variables
The results of the univariate and multivariate analysis of the patient-and transplant-related variables for the occurrence of HAdV infection are summarized in Table 5 . The use of ORD and MUD, 42 log TCD of the graft, HSCT from 1995 onwards and an age of the recipient at the time of HSCT of 5 years or younger were significantly and independently associated with an increased HAdV infection rate. Kaplan-Meier curves of HAdV-free survival in patients categorized according to these relevant variables are shown in Figure 1 . There was no significant relationship 
a HAdV infection occurred in 37 cases. In 20 of them, the infection provoked no symptoms and in 17 cases HAdV disease was observed, which had a fatal course in seven of them. between the original disease and the occurrence of HAdV infection, with the exception of MDS. In all, 10 out of the 41 patients treated for MDS developed an HAdV infection, of whom six with disease symptoms and one with fatal outcome. The median age of HAdV-infected patients (n ¼ 37) at the time of HSCT was 4.0 years (range 0.6-17.0) and that of the whole study population 6.8 years (range 0.04-19.3), also indicating that infection occurred preferentially at a younger age. In addition, the median age of children with an early (o30 days after HSCT) onset of infection (n ¼ 16) was 2.4 years compared with 8.3 years for children with a late (490 days after HSCT) onset (n ¼ 8, data not shown). Failure of engraftment/early rejection and a conditioning regimen supported by immunosuppression using (monoclonal) antibodies shortly before or over the date of transplant were risk factors with a borderline significance. After adjustment for donor type, both parameters were no longer associated with the occurrence of HAdV infection. In univariate analysis, the original disease (except for MDS), GvHD prophylaxis, the occurrence of acute GvHD and gender of the recipient turned out as nonsignificant risk factors for the occurrence of HAdV infection. The incidence of HAdV infection was significantly increased in patients receiving a second HSCT within 6 months after the first transplant (Po0.01, data not shown). No clear association was found between HAdV infection and the development of extensive chronic GvHD (P ¼ 0.08). The actuarial frequency and time relationship of the occurrence of an HAdV infection with an increasing number of major risk factors, as found in the univariate analysis, are shown in Figure 2 . In children aged 5 years or younger and transplanted in 1995 or later with a rigorously T-cell-depleted graft of an ORD/MUD, the actuarial frequency of HAdV infection at 6 months after HSCT was 84%.
Of the 37 recipients with positive HAdV cultures, 17 got HAdV disease. In 10 of them only enteritis could be attributed to HAdV. The Kaplan-Meier estimated incidence of HAdV disease was 6% in the whole study group and 15% in the recipients of a graft from an ORD/MUD.
Within the group of HAdV-infected patients, failure of engraftment/early rejection could be identified as being an additional risk factor for HAdV disease in logistic regression analysis (Table 6 ). None of the other parameters identified as risk factor for the occurrence of HAdV infection could be identified as separately being a risk factor for HAdV disease due to the relatively small number of cases.
Seven out of the 37 HAdV-infected recipients died due to the infection at a median of 42 days (range 20-346 days) after the first positive HAdV culture, resulting in a Kaplan- Table 6 Univariate logistic regression analysis of risk factors associated with the occurrence of HAdV disease and HAdV-related death in infected patients Children with none of these major risk factors (RF) (---); children with a single major risk factor or a random combination of two risk factors (À À); children with all three major risk factors (-). For children who had already HAdV-positive cultures prior to HSCT, the date of HAdV infection was set at day 0.
Meier estimated incidence of HAdV-associated death of 22% in infected patients. Only recipients of a graft from an ORD/MUD died as a result of HAdV infection. The incidence of a fatal outcome in this subgroup of HAdVpositive patients was 31%. Despite immunosuppression given shortly before or over the transplant date (Campath in three patients, combined with aLFA-1 and aCD2 in one, and ATG in two patients), failure of engraftment or rejection of the graft occurred in five recipients. In the other two patients with HAdV-related death, acute GvHD grade IV and extensive chronic GvHD developed, respectively, requiring corticosteroids and additional immunosuppressive treatment. TCD of the graft, only applied in case of an ORD/MUD, and failure of engraftment/early rejection were the only risk factors significantly associated with HAdV-related death (Table 6) , with only a 53% survival among HAdV-infected recipients of a rigorously TCD graft. Although a young age was associated with HAdV infection, children of 5 years of age or younger were not more likely to die from HAdV infection (death rate 19%) than children above 5 years of age (death rate 24%).
Immunological recovery
In total, 27 out of the 37 HAdV-infected cases, including 15 out of 17 children with HAdV disease and all of the seven children who died, were recipients of an ORD/MUD graft. Therefore, the search for a possible relation between immunological recovery and the occurrence of HAdV infection and its course was focused on this group of HSCT recipients. Peripheral blood counts of the total CD3 þ T-cell population as well as the CD3 þ CD4 þ and CD3 þ CD8 þ T-cell subsets at different time points after HSCT are presented in Figure 3 . The data indicate that recovery of T-cell immunity during the 3rd and 4th month after HSCT, that is, the period of occurrence of HAdV infection in the majority of patients, was significantly impaired in HAdV-infected patients compared with noninfected recipients of an ORD/MUD graft. In addition, at the time of the first diagnosis of HAdV infection, patients with HAdV-associated death had significantly lower counts of T cells and CD3 þ CD4 þ and CD3 þ CD8 þ T-cell subsets than the whole group of HAdV-infected children. With respect to humoral immunity, serum IgM and IgA levels during the 1st and 2nd month after HSCT, but not IgG levels, were significantly decreased in cases with HAdV infection in comparison with children without HAdV infection (Figure 4) . After correction for age, only IgM concentrations remained significantly decreased in HAdVinfected children (data not shown). IgM levels were not significantly different between HAdV-infected children and the subgroup of patients with HAdV-associated death.
Lymphocyte counts and DNA load in serum
In 21 out of the 23 patients with positive cultures at multiple time points after HSCT, the results of DNA load measurements in serum by RQ-PCR and the blood lymphocyte counts were evaluated for a period of 1 month after the day of the first positive culture. The results summarized in Figure 5 indicate that a positive PCR signal, suggestive for HAdV dissemination, or even a high DNA load in serum per se was not related with a fatal outcome of the infection. In nine of the 21 evaluated children, a DNA load higher than 1000 copies/ml was observed. Four of these nine children showed a rise of lymphocyte counts and survived. In the five remaining patients, lymphocyte counts dropped below 100/ml and the infection had a fatal course. In six out of seven patients with HAdV-related death, The results of statistical evaluation of differences (T-tests) between the noninfected children and HAdV-infected patients, patients with HAdV disease and patients with HAdV-associated death, respectively, were indicated (*P ¼ 0.04, **P ¼ 0.02, ***P ¼ 0.01). serum samples were available for DNA testing up to the time of decease. Only one patient had a DNA load below 1000 copies/ml. The infection in this patient was caused by HAdV 41 and probably limited to the gut as the major manifestation was a long-lasting and severe haemorrhagic enteritis.
Discussion
The incidence and outcome of HAdV infections in a cohort of 328 paediatric recipients of an allogeneic HSCT, consecutively transplanted in our centre during the period 1985-1999, was evaluated retrospectively. Despite the limitations of such a study, our data clearly show an increased incidence of HAdV infection from 5.4% before 1995 to 22.5% after 1995. A trend of an increasing incidence of HAdV infection has also been reported by Bruno et al exploring the time window from 1988 to 1999. 30 This could not be explained solely by the fact that in recent years a higher proportion of the patients is at risk for HAdV infection following transplantation with a 42 log TCD graft from an ORD or MUD, since the transplant period remained an independent risk factor in the multivariate analysis. Cross-infection during the hospital stay could be another potential factor in causing an increased incidence of HAdV infection during a distinct period. However, in view of the strict protective isolation measures taken in our HSCT unit, it is unlikely that cross-infection occurred in our cohort. Moreover, no clustering of infections due to a single HAdV serotype was observed. An explanation for the increased incidence might be that HAdV has become more apparent as detection and (preemptive) treatment of potentially fatal CMV and EBV infections improved in the course of time. An alternative explanation for the observed increase of HAdV infections after HSCT could be that in recent years the policy of treatment of children with recurrent ear, nose and throat infections changed, in that adenectomy is carried out much less frequently than in the past. This might be relevant because adenoid and tonsillar tissues are reported as sites harbouring HAdV. 31, 32 Unfortunately, this hypothesis could not be tested in this retrospective study because data on adenectomy and tonsillectomy were lacking from most of the patients' records.
Severe HAdV infections have been reported in patients with primary immunodeficiencies 33 and secondary immunodeficiencies such as AIDS, 34, 35 and solid organ [36] [37] [38] and bone marrow transplant recipients (reviewed in Walls et al 13 and Kojaoghlanian et al
14
)
. It has been suggested that HAdV infections after organ transplantation might be caused by transmission of the virus via the donor organ 36 or by nosocomial acquisition. 37 In the bone marrow transplant recipients, the majority of infections are probably reactivations of viruses latently present in the host 10, 15, 39 although some authors 6 question this. The observation that the HAdV serotype, detected in five out of six children with positive cultures before HSCT in our cohort, was identical to the type identified after HSCT gives some support to the hypothesis that reactivation of a latently persistent virus rather than de novo infection or transmission of the virus from donor occurs in HSCT recipients.
Previous studies on HAdV infection after HSCT have included children only, 5, 8, 12 adults only 16 or separately evaluated the data obtained in adult and paediatric cases. [9] [10] [11] In these studies, a trend towards a higher incidence of HAdV infections in children than in adults was observed. This observation of age-dependency of HAdV infection is further corroborated by our finding that the incidence of HAdV infection was higher in HSCT recipients p5 years of age than in children 45 years of age. It can be speculated that this is a reflection of agedependent exposure to HAdV. 40, 41 In this respect, it may be relevant that 17 out of the 26 typed HAdV isolates represented serotypes belonging to species C, that is, HAdV 1, 2, 5 and 6, known to be responsible for 480% of the first infections in infants and young children. [42] [43] [44] The original observation by Flomenberg et al 9 that children with an early onset of infection (o30 days after HSCT) are younger than children with a late (490 days after HSCT) onset of infection was confirmed in the present study.
In healthy children, the vast majority of first HAdV infections are upper respiratory tract infections and enteritis, a lesser proportion are exudative pharyngitis, conjunctivitis and seldom nonrespiratory illnesses. 41, 44 In congenital cellular immunodeficiencies and in secondary immunodeficiencies such as patients after HSCT, expression of HAdV infections differs from that in immunocompetent children. It includes haemorrhagic cystitis, (haemorrhagic) enteritis, pneumonia, hepatitis and encephalitis. 33, 34, 45 In our cohort, 17 children showed signs and symptoms attributed to HAdV infection and in seven of them the disease had a fatal course. Enteritis appeared as a common feature (15 out of 17 cases) and was associated with severe haemorrhagic cystitis and hepatitis in five out of seven fatal cases. In our study cohort, hepatitis (n ¼ 3) and pneumonia (n ¼ 1) were only observed in patients with a fatal outcome of the HAdV infection. However, our overall data indicated that the presentation of signs and symptoms apart from enteritis occurs rather late in the course of the disease and, for that reason, might be an inappropriate indicator to start treatment timely.
In previous studies, isolation of HAdV from multiple sites [9] [10] [11] or a positive HAdV RQ-PCR at multiple sites including peripheral blood 19 was identified as a risk factor for a fatal course of HAdV disease. Although our evaluation of the number of culture positive sites did not reach significance, the combination of HAdV isolation from other sites than the stool, persistence of the virus and signs and symptoms of dissemination (ie pneumonia and hepatitis) were associated with HAdV-related death in our retrospective study.
Disease parameters, except for the diagnosis of MDS, were not associated with an unfavourable course after HAdV infection in our study population. Except for the occurrence of severe symptoms of conditioning-related toxicity in MDS cases, 46 that is, mucosal damage of the oropharynx and GI-tract associated with melphalan as part of the conditioning possibly promoting HAdV translocation and spreading, we have no explanation for this finding. The occurrence of acute GvHD grade II-IV, the frequency of which was low (4.6%) in our study cohort, was not associated with the development of HAdV disease. This observation supports findings reported by some groups, 5, 15 but is in contrast with data from others. 9, 10, 16, 30 HSCT with a graft of an ORD/MUD and a 42 log TCD of the graft turned out to be independent risk factors for the occurrence of HAdV infection in our study cohort. As recovery of T-cell mediated immunity is delayed up to 6 months post transplantation under such HSCT conditions, 47 this observation suggests a role of T-cellular immune capacity to prevent HAdV reactivation. Among recipients of a graft from an ORD/MUD in our cohort, slow T-cell recovery based on the counts of CD3 þ T cells or CD4 þ and CD8 þ T-cell subsets, respectively, correlated significantly with the occurrence of HAdV infection. In addition, HAdV-infected patients with low T-cell counts are at risk for developing a fatal course of the disease. The latter observation is reminiscent to the findings recently reported by Chakrabarti et al, 17 who identified severe lymphocytopenia at the time of first detection of HAdV infection post-HSCT as a major risk factor for the development of HAdV disease. In liver transplant recipients, disseminated HAdV disease seems to be associated with the use of antirejection therapy with ATG or anti-CD3 monoclonal antibody. 36, 37, 48 ) has been reported as risk factor for the occurrence of HAdV infection. However, in our study cohort, we only observed significance of ATG, anti-CD52, anti-LFA1 or anti-CD2 antibodies on the incidence of HAdV infection in the univariate, not in the multivariate analysis. In order to elucidate the role of T cells in the prevention of HAdV reactivation and/or clearance of persistent HAdV infection more precisely, investigation of the HAdV-specific cellular immunity after HSCT is required as recently reported by our group. 49 Longitudinal evaluation of serum immunoglobulin levels in our patients revealed a diminished active humoral immunity, that is, low levels of IgM and IgA, early after HSCT to be associated with the occurrence of HAdV infection. Data from our group obtained in a prospective study cohort showed an association between the course of the titres of HAdV serotype-specific neutralizing antibodies after disseminated infection and the outcome of the infection. 49 In this respect, it is relevant to note that the majority of patients, including all recipients of an ORD/ MUD graft, receive i.v. IgG-substitution (IVIG) during the first 3 months after HSCT. Since IVIG batches contain only low amounts of neutralizing antibodies, it remains possible that administration of antisera containing high titres of neutralizing antibodies specific for the infectious HAdV serotype may prevent dissemination of HAdV infection as shown previously. 50 Only three cases in our study were treated with antiviral medication, that is, ribavirin or cidofovir, at the time severe clinical symptoms and high DNA loads in serum were present. Unfortunately, all three patients died from disseminated HAdV infection a few days after the start of treatment. In other studies, both successes and failures of ribavirin and/or cidofovir have been reported. 7, 8, 51, 52 From these reports it became clear that treatment should be installed at the first indication of dissemination of the infection. However, apart from one study on cidofovir, 51 attribution of the antiviral effect solely to the drug given remained elusive because data on the status of the immune competence at the time of infection were lacking.
Recently, we have reported that detection of HAdV DNA in serum or plasma by PCR either qualitatively 53 or semiquantitatively 18 may be a sensitive indicator of viral dissemination. The latter study has been performed in the same patient cohort as presented here, and the results indicated that there is a time window of several weeks between the first detection of a positive plasma PCR and the fatal course of disease. Recently, Lion et al 19 reached the same conclusion using PCR for the monitoring of peripheral blood samples. A high and increasing HAdV DNA load in plasma was shown to be a sensitive parameter for a fatal course of the infection. 54 However, data on immune reconstitution were lacking from these and other studies considering HAdV DNA load in plasma and outcome of the infection. [18] [19] [20] 54 Regular screening of patients at risk for dissemination of an HAdV infection is strongly recommended and will allow the initiation of preemptive treatment. Until now, there is no definite proof of efficacy of available antiviral drugs on disseminated HAdV infection. Previous reports have presented evidence that donor lymphocyte infusion or withdrawal of immunosuppressive treatment in cases with some reconstitution of cellular immunity may result in clearance of persistent HAdV infection after HSCT. 17, 55, 56 Adoptive cellular immunotherapy using either HAdV-specific T cells [57] [58] [59] [60] or T cells depleted from alloreactive cells 61 may offer novel therapeutic options. Based on the results of this retrospective study that are supported by recent data from a prospective study performed in our group, 49 we have defined patients eligible for adoptive immunotherapy. In our opinion, treatment should be considered in patients with an HAdV DNA load in serum/plasma of X1000 copies/ ml and showing an increase of the load in two consecutive samples taken within 1 week. At the same time, they should have low (o300/ml) peripheral blood lymphocyte counts not increasing over a period of 2 weeks following the first detection of the high DNA load. According to these criteria, four patients of this retrospective cohort would have been eligible for adoptive immunotherapy, that could have been initiated at 2-4 weeks before HAdVrelated death in these cases. Expansion of HAdV-specific T cells in cultures of donor PBMC will take a period of 4-6 weeks. To ensure that these cells are available for infusion at the first signs of viral dissemination, we propose that cultures have to be started at the time of HSCT for all children receiving a TCD graft from an MUD or ORD donor.
